Insider · CIK 0001599214
Bihua Chen
ownerotherceochairofficerdirector
Files at OKUR (OnKure Therapeutics, Inc.), AARD (Aardvark Therapeutics, Inc.), DRUG (BRIGHT MINDS BIOSCIENCES INC.), BMEA (Biomea Fusion, Inc.), BBOT (BridgeBio Oncology Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | MOption exercise Common Stockindirect: Via Helix Holdings II LLC | +4,172,126 | - | - | 4,681,126 | Aug 13, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | DDisposition to issuer Common Stockindirect: Via Helix Holdings II LLC | -152,940 | $0.00 | $0 | 4,528,186 | Aug 13, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Common Stockindirect: Via Fund III | +760,496 | $10.72 | $8.2M | 2,187,536 | Aug 13, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Common Stockindirect: Via Fund V | +639,110 | $10.72 | $6.8M | 1,542,710 | Aug 13, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Common Stockindirect: Via Master Fund | +5,598,425 | $10.72 | $60M | 5,667,785 | Aug 13, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Common Stockindirect: Via Fund IV | +1,905,046 | - | - | 1,905,046 | Aug 13, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Common Stockindirect: Via Fund V | +1,762,760 | - | - | 3,305,470 | Aug 13, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Common Stockindirect: Via Master Fund | +284,571 | - | - | 5,952,356 | Aug 13, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | DDisposition to issuer Class B ordinary sharesderivativeindirect: See footnote | -307,874 | $0.00 | $0 | 4,172,126 | Aug 13, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | MOption exercise Class B ordinary sharesderivativeindirect: See footnote | -4,172,126 | - | - | 0 | Aug 13, 2025 |
| Jun 11, 2025 | BMEA Biomea Fusion, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +91,970 | $0.00 | $0 | 91,970 | Jun 13, 2025 |
| Feb 8, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | JOther Class B Ordinary Sharesderivativeindirect: See Footnote | -30,000 | $0.00 | $0 | 4,480,000 | Feb 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.